Home > Insider Trading > Filing (0000950170-24-002279)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818794	Dyne Therapeutics Inc.	DYN	Pharmaceutical Preparations (2834)	364883909

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1824542	Oxana Beskrovnaya	1560 Trapelo Road Waltham MA 02451	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-01-03	45,326	$1.03	221,911	No	4	M	Direct
Common Stock	Disposition	2024-01-03	15,382	$18.34	206,529	No	4	S	Direct
Common Stock	Disposition	2024-01-03	24,583	$19.05	181,946	No	4	S	Direct
Common Stock	Disposition	2024-01-03	5,361	$20.50	176,585	No	4	S	Direct
Common Stock	Acquisiton	2024-01-04	22,674	$1.03	199,259	No	4	M	Direct
Common Stock	Disposition	2024-01-04	42,453	$18.13	156,806	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2024-01-03	45,326	$0.00	45,326	$1.03
Common Stock	Stock option (right to buy)	Disposition	2023-01-04	22,674	$0.00	22,674	$1.03

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
53,100		2030-01-05	No	4	M	Direct
30,426		2030-01-05	No	4	M	Direct

Footnotes

Includes 146,805 unvested RSUs.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.50 to $20.56, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.45, inclusive.
The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on January 27, 2021 and the remaining shares vesting in equal quarterly installments thereafter.